Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI-generated claims partially align with the label. It correctly reflects some mechanisms, indications (dysmenorrhea and arthritis-related pain), and the concept that naproxen is an NSAID with prostaglandin inhibition. It overextends by citing brand-specific indications (e.g., headaches, common cold), implying OTC/brand details not explicitly stated in the provided label, and omits critical safety elements such as contraindications, boxed warnings, pregnancy/pediatric considerations, and explicit dosing limits.
Category Scores
Accurate Statements
Naproxen blocks production of prostaglandins.
12.1
Naproxen has analgesic, anti-inflammatory, and antipyretic properties.
12.1
Prostaglandins are mediators of inflammation.
12.1
Naproxen-containing products should not be used concomitantly since they all circulate in the plasma as the naproxen anion.
2.1
Naproxen is an NSAID used for pain and inflammation relief.
12.1
Aleve contains naproxen sodium.
16
Aleve is used to temporarily relieve menstrual cramps.
1
Aleve is used to temporarily relieve minor pain and inflammation of arthritis.
1
Unsupported Statements
Naproxen is available over-the-counter.
The label excerpt does not explicitly state OTC status.
The brand name for naproxen is Aleve.
Brand names are not discussed in the provided label sections.
Aleve is used to temporarily relieve headaches.
Headache relief is not listed among the label's indications.
Aleve is used to temporarily relieve backaches.
Backache relief is not listed among the label's indications.
Aleve is used to temporarily relieve the common cold.
Common cold relief is not listed among the label's indications.
Naproxen typically lasts longer in the body than ibuprofen.
The label provides naproxen pharmacokinetics but does not compare to ibuprofen.
Because of this, naproxen may be taken less frequently for continuous pain relief.
The label states to use the lowest effective dose for the shortest duration, but does not explicitly claim less frequent dosing vs ibuprofen based on duration.
Drug patent exclusivity for naproxen has long expired.
No patent/exclusivity discussion is present in the provided label sections.
This allows for generic versions and over-the-counter availability.
Generic/OTC availability is not explicitly discussed in the provided label sections.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims focus on basic pharmacology and indications with limited safety detail; critical safety elements (contraindications, boxed warnings, pregnancy/pediatric considerations) are not addressed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Brand-specific indications and OTC status not explicit in label; missing safety warnings and contraindications; dosing/administration specifics not addressed.
Suggested Improvement
Limit statements to those supported by the label; remove brand-name and non-listed indications (headache, common cold); explicitly reference contraindications, boxed warnings, pregnancy/pediatric considerations, and dosing limits (e.g., max daily dose and dosing interval) from the label.